In Iselin, New Jersey, on December 26, 2025, Outlook Therapeutics, Inc. revealed that it granted stock options to acquire 150,000 shares of the company's common stock to two fresh employees on December 19, 2025. These options have an exercise price of $2.01 per share. This move was made by the Compensation Committee of the Board of Directors to boost the standard of care for bevacizumab in treating retina diseases. Outlook Therapeutics, Inc. is a biopharmaceutical company traded on Nasdaq under the symbol OTLK.